MX2018001905A - Metodos para el tratamiento del virus de hepatitis c (vhc). - Google Patents
Metodos para el tratamiento del virus de hepatitis c (vhc).Info
- Publication number
- MX2018001905A MX2018001905A MX2018001905A MX2018001905A MX2018001905A MX 2018001905 A MX2018001905 A MX 2018001905A MX 2018001905 A MX2018001905 A MX 2018001905A MX 2018001905 A MX2018001905 A MX 2018001905A MX 2018001905 A MX2018001905 A MX 2018001905A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- methods
- weeks
- compound
- pharmaceutically acceptable
- Prior art date
Links
- 239000003443 antiviral agent Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 229940125782 compound 2 Drugs 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 229960000329 ribavirin Drugs 0.000 abstract 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/431,906 US11484534B2 (en) | 2013-03-14 | 2017-02-14 | Methods for treating HCV |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018001905A true MX2018001905A (es) | 2018-11-09 |
Family
ID=61192811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018001905A MX2018001905A (es) | 2017-02-14 | 2018-02-14 | Metodos para el tratamiento del virus de hepatitis c (vhc). |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3360555A1 (enExample) |
| JP (1) | JP2018131439A (enExample) |
| CN (1) | CN108421029A (enExample) |
| AU (1) | AU2018201011A1 (enExample) |
| BR (1) | BR102018002956A2 (enExample) |
| CA (1) | CA2994496A1 (enExample) |
| MX (1) | MX2018001905A (enExample) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0416902A (pt) * | 2003-12-11 | 2007-01-16 | Schering Corp | inibidores de ns3/ns4a serina protease do vìrus da hepatite c |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| KR102163902B1 (ko) | 2010-09-21 | 2020-10-12 | 이난타 파마슈티칼스, 인코포레이티드 | 매크로사이클릭 프롤린 유도된 ｈｃｖ 세린 프로테아제 억제제 |
| PH12014500832A1 (en) * | 2011-10-21 | 2022-12-02 | Abbvie Inc | Methods for treating hcv |
| SG2014011670A (en) | 2011-10-21 | 2014-10-30 | Abbvie Inc | Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv |
| TW202002979A (zh) * | 2013-03-14 | 2020-01-16 | 美商艾伯維有限公司 | 治療hcv的方法 |
| MX362616B (es) * | 2013-03-14 | 2019-01-28 | Abbvie Inc | Combinacion de dos agentes antivirales para el tratamiento de hepatitis c. |
| CN106413711A (zh) * | 2014-04-02 | 2017-02-15 | 艾伯维公司 | 治疗hcv的方法 |
| HK1255481A1 (zh) * | 2015-07-08 | 2019-08-16 | Abbvie Inc. | 用於治疗hcv的方法 |
-
2018
- 2018-02-09 CA CA2994496A patent/CA2994496A1/en active Pending
- 2018-02-09 JP JP2018021874A patent/JP2018131439A/ja active Pending
- 2018-02-12 EP EP18156337.0A patent/EP3360555A1/en not_active Withdrawn
- 2018-02-12 AU AU2018201011A patent/AU2018201011A1/en not_active Abandoned
- 2018-02-13 CN CN201810149405.XA patent/CN108421029A/zh active Pending
- 2018-02-14 MX MX2018001905A patent/MX2018001905A/es unknown
- 2018-02-15 BR BR102018002956A patent/BR102018002956A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018131439A (ja) | 2018-08-23 |
| CN108421029A (zh) | 2018-08-21 |
| CA2994496A1 (en) | 2018-08-14 |
| AU2018201011A1 (en) | 2018-08-30 |
| EP3360555A1 (en) | 2018-08-15 |
| BR102018002956A2 (pt) | 2018-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020005054A (es) | Combinacion de dos agentes antivirales para el tratamiento de hepatitis c. | |
| MX388482B (es) | Métodos para tratar el virus de la hepatitis c. | |
| EA201890507A1 (ru) | Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv | |
| MX2018000240A (es) | Metodos para tratar el vhc. | |
| PH12014502848A1 (en) | Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon | |
| PH12018550201A1 (en) | Hepatitis b antiviral agents | |
| PH12014500833A1 (en) | Methods for treating hcv | |
| PH12018550150A1 (en) | Elimination of hepatitis b virus with antiviral agents | |
| PH12020550065A1 (en) | Hepatitis b antiviral agents | |
| MX2016012722A (es) | Metodos para tratar el virus de la hepatitis c. | |
| PH12021550632A1 (en) | Monomer and multimeric anti-hbv agents | |
| MX2021002147A (es) | Tratamiento de la infección por virus de la hepatitis delta con interferón lambda. | |
| RU2015114566A (ru) | Способы лечения гепатита с | |
| WO2016090107A3 (en) | Treatment of hepatitis delta virus infection | |
| MX2020001422A (es) | Metodos para el tratamiento de hcv. | |
| MX2018001905A (es) | Metodos para el tratamiento del virus de hepatitis c (vhc). | |
| AU2019384793A8 (en) | Methods for treating acute HCV | |
| NZ631789A (en) | Combination of direct acting antiviral agents and ribavirin for treating hcv patients | |
| MX2018000213A (es) | Metodos para tratar el vhc. | |
| UA101772U (uk) | Спосіб лікування хронічного вірусного гепатиту с із супутньою неалкогольною жировою хворобою печінки | |
| ES2572355A2 (es) | Combinacion de aad para uso en el tratamiento del vhc |